ADCs are monoclonal antibodies conjugated with cytotoxic agents delivered once it attaches to the leukemic cell 225Ac-lintuzumab (CD33 radioimmunoconjugate), Iomab-B (CD45 radioimmunoconjugate), IMGN779 (CD33 ADC)—gemtuzumab ozogamicin, the first antibody–drug conjugate approved for induction therapy of AML, and IMGN632 (CD123 ADC). The gene discussed is CD33; the disease is acute myeloid leukemia.